Pathstone Family Office’s BioSpecifics Technologies Corp. BSTC Stock Holding History

Pathstone Family Office’s Portfolio BSTC Stock Details BSTC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-160	Closed	-$9K	–	1046
2020 Q1	$9K	Buy	+160	New	+$9.12K	﹤0.01%	558
2019 Q4	–	Sell	-160	Closed	-$9K	–	667
2019 Q3	$9K	Hold	160	–	–	﹤0.01%	500
2019 Q2	$10K	Buy	+160	New	+$10.1K	﹤0.01%	529

Other funds holding BSTC

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return

RHJA

Rice Hall James & Associates San Diego, California $1.8B AUM 36.16% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Royce & Associates New York $10.1B AUM 42.88% 1-Year Est. Return

Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return

Pathstone Family Office's BSTC Position: Q2 2020 in Review

Pathstone Family Office sold out of BioSpecifics Technologies Corp. (BSTC) in Q2 2020, closing a stake of 160 shares — an estimated $9K sold.

Pathstone Family Office first reported a position in BSTC in Q2 2019 and held it in 3 quarters. The position peaked at $10K in Q2 2019. 116 funds tracked by Wall St. Rank hold BSTC as of Q2 2020.

Pathstone Family Office reported no remaining BioSpecifics Technologies Corp. position as of Q2 2020 after selling out during the quarter.
Pathstone Family Office sold 160 BioSpecifics Technologies Corp. shares in Q2 2020, an estimated $9K.
Pathstone Family Office first reported a position in BioSpecifics Technologies Corp. in Q2 2019 and held it in 3 quarters.
Pathstone Family Office's BioSpecifics Technologies Corp. position peaked at $10K in Q2 2019.
116 funds tracked by Wall St. Rank held BioSpecifics Technologies Corp. as of Q2 2020.

Based on Pathstone Family Office's 13F filing for Q2 2020, filed 14 Aug 2020.